Search

Displaying results 1071 - 1080 of 3888 in total
  1. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

    Categories: DNA Terminase Complex Inhibitors, Cytomegalovirus DNA Terminase Complex Inhibitor
  2. Drug

    Podofilox

    go.drugbank.com/drugs/DB01179
    Approved

    It is very irritating to skin and mucous membranes, has keratolytic actions, has been used to treat warts and keratoses, and may have antineoplastic properties, as do some of its congeners and derivatives

  3. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively.

    Categories: Poly (ADP-ribose) polymerase (PARP) inhibitors
  4. Drug

    Tislelizumab

    go.drugbank.com/drugs/DB14922
    ApprovedInvestigational

    [L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349] … [A262924] On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA.

  5. Drug

    Fostamatinib

    go.drugbank.com/drugs/DB12010
    ApprovedInvestigational

    Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...

  6. Drug

    Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine

    go.drugbank.com/drugs/DB10061
    ApprovedInvestigational

    conjugate vaccine contains serogroup A, C, Y, and W-135 oligosaccharides conjugated individually to _Corynebacterium diphtheriae_ CRM197 protein carrier, resulting in four drug substances contained in each dose

  7. Target

    Holliday junction branch migration complex subunit RuvB

    go.drugbank.com/bio_entities/BE0001514
    TargetThermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099)

    The RuvA-RuvB-RuvC complex processes Holliday junction (HJ) DNA during genetic recombination and DNA repair, while the RuvA-RuvB complex plays an important role in the rescue of blocked DNA replication … The RuvB hexamer acts as an ATP-dependent pump, pulling dsDNA into and through the RuvAB complex.

    Polypeptides: Holliday junction branch migration complex subunit RuvB
  8. Target

    Cytochrome b6-f complex iron-sulfur subunit

    go.drugbank.com/bio_entities/BE0002474
    TargetMastigocladus laminosus

    Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.

    Polypeptides: Cytochrome b6-f complex iron-sulfur subunit
  9. Target

    Cytochrome b-c1 complex subunit Rieske, mitochondrial

    go.drugbank.com/bio_entities/BE0003858
    TargetHumans

    Component of the ubiquinol-cytochrome c oxidoreductase, a multisubunit transmembrane complex that is part of the mitochondrial electron transport chain which drives oxidative phosphorylation (PubMed:31883641 … The respiratory chain contains 3 multisubunit complexes succinate dehydrogenase (complex II, CII), ubiquinol-cytochrome c oxidoreductase (cytochrome b-c1 complex, complex III, CIII) and cytochrome c oxidase

    Polypeptides: Cytochrome b-c1 complex subunit Rieske, mitochondrialSynonyms: Complex III subunit 5, Cytochrome b-c1 complex subunit 5
  10. Target

    Major histocompatibility complex class I-related protein 1

    go.drugbank.com/bio_entities/BE0003573
    TargetHumans

    In complex with B2M preferentially presents riboflavin-derived metabolites to semi-invariant TRAV1.2 TCRs on MAIT cells, guiding immune surveillance of the microbial metabolome at mucosal epithelial barriers … May present microbial antigens to various TRAV1-2-negative MAIT cell subsets, providing for unique recognition of diverse microbes, including pathogens that do not synthesize riboflavin (PubMed:27527800

    Polypeptides: Major histocompatibility complex class I-related protein 1